In celebration of 15 years of “bringing beautiful to life,” RapidLash® has donated $68,000 to Project Purple to support the mission of a world without pancreatic cancer. RapidLash’s year-long “Paint It Purple” campaign showcased the power of community and compassion as its employees and customers came together for the company’s largest philanthropic effort to date.
“We are thrilled to have joined forces with RapidLash to Paint It Purple throughout the year,” said Dino Verrelli, founder and CEO of Project Purple. “Fighting one of our country’s deadliest cancers takes a village and corporate partners like RapidLash are critical in our fight. This gift and the public awareness raised through the Paint It Purple campaign are instrumental in our efforts to positively affect patient care and survival rates.”
Throughout 2023, a portion of every purchase of RapidLash eyelash, brow, hair and skin care products went to Project Purple, resulting in a $68,000 total donation. The donation enables Project Purple to provide the equivalent of:
- 1,889 pancreatic cancer patients with a care blanket;
- 137 patients with mortgage or rent payments;
- 876 patients with funding to keep their utilities running; or
- 398 patients the money to pay for medical expenses.
“Teaming up with Project Purple to combat pancreatic cancer has been a deeply personal journey for all of us,” said Janet Carieri, Chairwoman of RapidLash®. “We’re incredibly humbled that our employees and customers rallied behind this important mission. I couldn’t be prouder of what we’ve achieved together. To our cherished customers and the dedicated team at Project Purple, thank you for making 2023 truly remarkable.”
Project Purple welcomes the support of corporate partners through custom community giving programs similar to RapidLash’s Paint It Purple campaign or by sponsoring our Charity Golf Classic and our Pickleball Classic. Companies can also create teams and join one of our virtual events each year in honor or memory of a valued team member who was diagnosed with pancreatic cancer. Contact us here for more information.
